Anticancer Activity of Intravesical Glyceryl Monooleate (GMO)-Paclitaxel Therapy in Murine Superficial Transitional Cell Carcinoma Model Induced by BBN.
10.4111/kju.2006.47.11.1155
- Author:
Hyun Sop CHOE
1
;
Sae Woong KIM
;
Yong Hyun CHO
Author Information
1. Department of Urology, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Paclitaxel;
Intravesical administration;
Bladder cancer
- MeSH:
Administration, Intravesical;
Animals;
Bacillus;
Biological Availability;
Bone Marrow;
Carcinoma, Transitional Cell*;
Drinking Water;
Drug Therapy;
Humans;
Incidence;
Kidney;
Liver;
Mice;
Mucous Membrane;
Paclitaxel;
Urinary Bladder;
Urinary Bladder Neoplasms
- From:Korean Journal of Urology
2006;47(11):1155-1160
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose: Paclitaxel, on systemic administration, is widely known to be effective in the treatment of bladder cancer. However, the intravesical use of paclitaxel has not been attempted because of its liposolubility and direct toxicity to the bladder mucosa. The purpose of this study was to evaluate the efficacy and toxicity of paclitaxel-loaded glyceryl monooleate (GMO) in the intravesical treatment of superficial bladder cancer, by enhancing its bioadhesiveness and bioavailability. Materials and Methods: 12 mice were divided into two groups, and bladder carcinomas induced by the addition of 0.05% BBN to their drinking water for 12 weeks. Group 1 received an intravesical instillation of 0.1ml GMO-paclitaxel-free buffer and Group 2 an intravesical instillation of 0.1ml GMO-paclitaxel. On day 21, the tumor incidence, bladder weight and toxicity were evaluated. Results: The incidence of cancer in groups 1 and 2 were 83 and 17%, respectively. The incidence of cancer was significantly reduced in group 2 compared to group 1 (p<0.05). There was a tendency for the average bladder weight in group 1 to be heavier than that in group 2, but there was no significant difference (p=0.375). There were no liver, kidney or bone marrow toxicities in either group. Conclusions: Intravesical GMO-paclitaxel therapy may have an inhibitory effect on the growth of superficial bladder cancer in a BBN-induced bladder cancer model; therefore, it could potentially be used in those patients showing little to no response to intravesical Bacillus Calmette- Guerin (BCG) or other anticancer drug therapies.
